Status: Recruiting
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer
Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.
Participants needed: 250
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: Heinrich-Heine University, DuesseldorfUpdated: Jan 17, 2025Locations: 1
Eligibility criteria
Informed Consent [+1]
Technical Flaws in the acquisition protocol